312
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive
multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80. - Cominelli F. Inhibition of leukocyte trafficking in inflammatory bowel disease. N Engl J Med.
2013;369:775–6. - Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance ther-
apy for Crohn’s disease. N Engl J Med. 2013;369:711–21. - Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and
Crohn’s disease. Gut. 2016;66(5):839–51. - Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for
patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed.
Gastroenterology. 2014;147:618–27.e3. - Armuzzi A, Felice C. Etrolizumab in moderate-to-severe ulcerative colitis. Lancet.
2014;384:285–6. - Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a
randomised, controlled, phase 2 trial. Lancet. 2014;384:309–18. - Fiorino G, Gilardi D, Danese S. The clinical potential of etrolizumab in ulcerative colitis:
hypes and hopes. Therap Adv Gastroenterol. 2016;9:503–12. - Reinisch W, Sandborn W, Danese S, et al. A randomized, multicenter double-blind, placebo-
controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF)
in patients with moderate to severe ulcerative colitis: results of the TURANDOT study.
Gastroenterology. 2015;148:S1193–5. - Khanna R, Feagan BG. Emerging therapies for inflammatory bowel diseases. Dig Dis.
2016;34(Suppl 1):67–73. - Sandborn W, Lee SD, Tarabar D, et al. Anti-MAdCAM-1 antibody (PF-00547659) for active
refractory Crohn’s disease: results of the OPERA study. Gastroenterology. 2015;148:S162-S. - Reinisch W, Vermeire S, Cataldi F, et al. Anti-MAdCAM monoclonal antibody PF-00547659
does not affect immune surveillance in the central nervous system of crohn’s disease patients
who are anti-TNF inadequate responders: results from the Tosca study. Gastroenterology.
2014;146:S150-S. - Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for
ulcerative colitis. N Engl J Med. 2016;374:1754–62. - Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the
management of inflammatory bowel disease? Expert Opin Investig Drugs. 2016;25:709–18. - Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem.
2004;92:913–22. - Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to tar-
geted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719–29. - Deepak P, Loftus EV Jr. Ustekinumab in treatment of Crohn’s disease: design, development,
and potential place in therapy. Drug Des Devel Ther. 2016;10:3685–98. - Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol.
2017;52:141–50. - Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in
refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28. - Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy
for Crohn’s disease. N Engl J Med. 2016;375:1946–60. - Feagan BG, Sandborn W, Panes J, et al. Efficacy and safety of induction therapy with the
selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn’s disease:
results of a randomized, double-blind, placebo-controlled phase II study. Gastroenterology.
2016;150:S1266-S. - Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9:167–81.
- Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a tar-
get for inflammatory and autoimmune diseases: current and future prospects. Drugs.
2017;77(5):521–46.
F. Velayos